Peer-Reviewed Publications

      An 8-month systems toxicology inhalation/cessation study in Apoe−/− mice to investigate cardiovascular and respiratory exposure effects of a candidate Modified Risk Tobacco Product, THS 2.2, compared with conventional cigarettes

      Phillips, B.; Veljkovic, E.; Boué, S.; Schlage, W. K.; Vuillaume, G.; Martin, F.; Titz, B.; Leroy, P.; Buettner, A.; Elamin, A.; Oviedo, A.; Cabanski, M.; De León, H.; Guedj, E.; Schneider, T.; Talikka, M.; Ivanov, N. V.; Vanscheeuwijck, P.; Peitsch, M. C.; Hoeng, J.

      Published
      Nov 25, 2015
      DOI
      10.1093/toxsci/kfv243
      PMID
      26609137
      Link to publication
      Topic
      Summary

      Smoking cigarettes is a major risk factor in the development and progression of cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD). Modified risk tobacco products (MRTPs) are being developed to reduce smoking-related health risks. The goal of this study was to investigate hallmarks of COPD and CVD over an 8-month period in apolipoprotein E-deficient mice exposed to conventional cigarette smoke (CS) or to the aerosol of a candidate MRTP, THS2.2. In addition to chronic exposure, cessation or switching to THS2.2 after 2 months of CS exposure was assessed. Engaging a systems toxicology approach, exposure effects were investigated using physiology and histology combined with transcriptomics, lipidomics, and proteomics. CS induced nasal epithelial hyperplasia and metaplasia, lung inflammation, and emphysematous changes (impaired pulmonary function and alveolar damage). Atherogenic effects of CS exposure included altered lipid profiles and aortic plaque formation. Exposure to THS2.2 aerosol (nicotine concentration matched to CS, 29.9 mg/m3) did not induce lung inflammation or emphysema, nor did it consistently change the lipid profile or enhance the plaque area. Cessation or switching to THS2.2 reversed the inflammatory responses and halted progression of initial emphysematous changes and the aortic plaque area. Biological processes, including senescence, inflammation, and proliferation, were significantly impacted by CS, but not by THS2.2 aerosol. Both, cessation and switching to THS2.2 reduced these perturbations to almost sham exposure levels. In conclusion, in this mouse model cessation or switching to THS2.2 retarded the progression of CS-induced atherosclerotic and emphysematous changes, while THS2.2 aerosol alone had minimal adverse effects.

      Related Publications

      Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System 2.2

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

      Aerosol Chemistry

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.